← Leaderboards
Frederick C. Wang
Brigham And Women'S Hospital
$16,331,006
Attributed
$16,331,006
Total exposure
32
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$22,620,784 · 33
By mechanism
R01$11,898,324 · 4
P01$6,944,684 · 2
P51$2,475,620 · 25
RC2$1,025,640 · 1
R21$276,516 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Benjamin Elison Gewurz$12,892,911
- Chong Wang$1,369,010
- Eric C Johannsen$4,978,414
- Rui Guo$978,211
- Elliott D Kieff$27,601,410
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaImmune ResponseInfectionEpstein-Barr Virus InfectionsLymphocryptovirusGenesViralHuman Herpesvirus 4FundingHerpesviridae DiseaseAcuteAnimal ModelImmuneGammaherpesvirinaeDisease /Disorder ModelViral ProteinsInfected B CellAcquired Immunodeficiency SyndromeVirusEbv-Associated DiseasePathogenesisSourceUnited States National Institutes Of HealthCells
Grant awards (70)
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection$593,287
R01 · FY2019 · AI · contact PI
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection$593,287
R01 · FY2018 · AI · contact PI
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection$593,287
R01 · FY2017 · AI · contact PI
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection$612,662
R01 · FY2016 · AI · contact PI
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection$434,048
R01 · FY2015 · AI · contact PI
Pathogenesis of EBV Infection$435,089
R01 · FY2014 · CA · contact PI
Pathogenesis of EBV Infection$423,802
R01 · FY2013 · CA · contact PI
Pathogenesis of EBV Infection$453,231
R01 · FY2012 · CA · contact PI
Pathogenesis of EBV Infection$454,973
R01 · FY2011 · CA · contact PI
Pathogenesis of oral rhesus lymphocryptovirus infection$359,692
R01 · FY2011 · DE · contact PI
A THERAPEUTIC VACCINE FOR EBV-ASSOCIATED MALIGNANCIES$68,415
P51 · FY2011 · RR · contact PI
EPSTEIN-BARR VIRUS: A PERSISTENT VACCINE VECTOR$68,415
P51 · FY2011 · RR · contact PI
PATHOGENESIS OF ORAL RHESUS LYMPHOCRYPTOVIRUS INFECTION$68,415
P51 · FY2011 · RR · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$68,415
P51 · FY2011 · RR · contact PI
Epstein-Barr Virus: A persistent vaccine vector$529,459
RC2 · FY2010 · CA · contact PI
Pathogenesis of EBV Infection$469,785
R01 · FY2010 · CA · contact PI
Pathogenesis of oral rhesus lymphocryptovirus infection$370,817
R01 · FY2010 · DE · contact PI
PATHOGENESIS OF EBV INFECTION IN THE RHESUS MACAQUE ANIMAL MODEL$202,435
P51 · FY2010 · RR · contact PI
PATHOGENESIS OF ORAL RHESUS LYMPHOCRYPTOVIRUS INFECTION$65,759
P51 · FY2010 · RR · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$65,759
P51 · FY2010 · RR · contact PI
EPSTEIN-BARR VIRUS: A PERSISTENT VACCINE VECTOR$65,759
P51 · FY2010 · RR · contact PI
Epstein-Barr Virus: A persistent vaccine vector$496,181
RC2 · FY2009 · CA · contact PI
Pathogenesis of Epstein-Barr Virus Infection$417,501
R01 · FY2009 · CA · contact PI
Pathogenesis of oral rhesus lymphocryptovirus infection$374,562
R01 · FY2009 · DE · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$111,945
P51 · FY2009 · RR · contact PI
PATHOGENESIS OF ORAL RHESUS LYMPHOCRYPTOVIRUS INFECTION$111,945
P51 · FY2009 · RR · contact PI
Pathogenesis of Epstein-Barr Virus Infection$407,881
R01 · FY2008 · CA · contact PI
Pathogenesis of oral rhesus lymphocryptovirus infection$374,562
R01 · FY2008 · DE · contact PI
PATHOGENESIS OF ORAL RHESUS LYMPHOCRYPTOVIRUS INFECTION$237,907
P51 · FY2008 · RR · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$237,907
P51 · FY2008 · RR · contact PI
Pathogenesis of Epstein-Barr Virus Infection$403,843
R01 · FY2007 · CA · contact PI
Pathogenesis of oral rhesus lymphocryptovirus infection$378,728
R01 · FY2007 · DE · contact PI
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$103,634
P51 · FY2007 · RR · contact PI
NEW WORLD ONCOGENIC LYMPHOCRYPTOVIRUSES$103,634
P51 · FY2007 · RR · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$103,634
P51 · FY2007 · RR · contact PI
Pathogenesis of Epstein-Barr Virus Infection$403,788
R01 · FY2006 · CA · contact PI
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$134,807
P51 · FY2006 · RR · contact PI
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$66,311
P51 · FY2006 · RR · contact PI
NEW WORLD ONCOGENIC LYMPHOCRYPTOVIRUSES$66,311
P51 · FY2006 · RR · contact PI
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$1,342,294
P01 · FY2005 · DE
Pathogenesis of Epstein-Barr Virus Infection$400,982
R01 · FY2005 · CA
New World Oncogenic Lymphocryptoviruses$276,274
R01 · FY2005 · CA
Oral pathogenesis of rhesus and human lymphocryptovirus infection$202,319
P01 · FY2005 · DE
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$69,059
P51 · FY2005 · RR
NEW WORLD ONCOGENIC LYMPHOCRYPTOVIRUSES$33,521
P51 · FY2005 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$33,521
P51 · FY2005 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$1,303,223
P01 · FY2004 · DE
New World Oncogenic Lymphocryptoviruses$276,274
R01 · FY2004 · CA
Oral pathogenesis of rhesus and human lymphocryptovirus infection$196,445
P01 · FY2004 · DE
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$64,424
P51 · FY2004 · RR
NEW WORLD ONCOGENIC LYMPHOCRYPTOVIRUSES$35,475
P51 · FY2004 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$35,475
P51 · FY2004 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$1,263,718
P01 · FY2003 · DE
PATHOGENESIS OF EPSTEIN BARR VIRUS INFECTION$406,170
R01 · FY2003 · CA
New World Oncogenic Lymphocryptoviruses$276,274
R01 · FY2003 · CA
Oral pathogenesis of rhesus and human lymphocryptovirus infection$128,071
P01 · FY2003 · DE
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION$101,403
P51 · FY2003 · RR
MODEL FOR EBV IMMUNE RESPONSES$101,403
P51 · FY2003 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$24,966
P51 · FY2003 · RR
NEW WORLD ONCOGENIC LYMPHOCRYPTOVIRUSES$24,966
P51 · FY2003 · RR
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$1,224,914
P01 · FY2002 · DE
PATHOGENESIS OF EPSTEIN BARR VIRUS INFECTION$396,473
R01 · FY2002 · CA
New World Oncogenic Lymphocryptoviruses$275,896
R01 · FY2002 · CA
Oral pathogenesis of rhesus and human lymphocryptovirus infection$128,071
P01 · FY2002 · DE
ORAL PATHOGENESIS OF GAMMAHERPESVIRUS INFECTIONS$1,155,629
P01 · FY2001 · DE
PATHOGENESIS OF EPSTEIN BARR VIRUS INFECTION$386,482
R01 · FY2001 · CA
New World Oncogenic Lymphocryptoviruses$273,819
R01 · FY2001 · CA
A MODEL FOR EPSTEIN-BARR VIRUS INDUCED IMMUNE RESPONSES$138,258
R21 · FY2001 · RR
PATHOGENESIS OF EPSTEIN BARR VIRUS INFECTION$374,855
R01 · FY2000 · CA
A MODEL FOR EPSTEIN-BARR VIRUS INDUCED IMMUNE RESPONSES$138,258
R21 · FY2000 · RR